ESC HF 2023 What are the results of an open-label extension study of the APOLLO-B trial with patisiran in patients with ATTR cardiac amyloidosis? Prof. Fontana provides a brief summary.
This video was recorded during the ESC Heart Failure 2023 in Prague, Czech Republic.
Marianna Fontana is the Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, VK.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- ESC Heart Failure 2023Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
Ahmad Masri, MD
- ESC Heart Failure 2023Benefits of rapid uptitration of HF medications independent of baseline renal function
Jozine ter Maaten, MD, PhD
- ESC Heart Failure 2023Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
Jasper Brugts, MD, PhD
- ESC Heart Failure 2023ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF
Robert Mentz, MD